Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...
(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback